Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Effective management ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to deliver up to 10 clinical ...

Please provide your email address to receive an email when new articles are posted on . Air pollution and genetic susceptibility increased the risks for progression from asthma to COPD, according to a ...

Please provide your email address to receive an email when new articles are posted on . The likelihood for cardiovascular disease increased with impaired vs. normal spirometry findings. Individuals ...

Prednisone reduces hospital stay duration and mortality in COPD and heart failure patients compared to other corticosteroids. The study analyzed data from 6,153 patients admitted to HCA Healthcare ...

NEW YORK, Sept. 20 (UPI) --Recent advances in chronic obstructive pulmonary disease offer patients more hope in easing discomfort from a condition that can cause severe airflow blockage and ...

A recent study found that a nurse practitioner/community health worker intervention was a feasible and acceptable strategy for addressing how social determinants of health (SDOH) and comorbidities ...

AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...